Novo Nordisk ROA 2006-2018 | NVO

Current and historical return on assets (ROA) values for Novo Nordisk (NVO) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Novo Nordisk ROA for the three months ending September 30, 2018 was 38.73%.
Novo Nordisk ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $6.16B $15.90B 38.86%
2018-06-30 $6.30B $16.53B 39.97%
2018-03-31 $6.11B $15.45B 40.12%
2017-12-31 $5.79B $15.55B 39.27%
2017-09-30 $5.73B $15.47B 39.52%
2017-06-30 $5.65B $14.47B 40.67%
2017-03-31 $5.69B $13.51B 41.77%
2016-12-31 $5.64B $14.49B 42.38%
2016-09-30 $5.59B $13.10B 42.68%
2016-06-30 $5.37B $13.41B 41.31%
2016-03-31 $5.09B $12.18B 40.22%
2015-12-31 $5.19B $13.66B 41.37%
2015-09-30 $5.08B $12.70B 40.42%
2015-06-30 $4.98B $12.05B 39.69%
2015-03-31 $5.03B $11.74B 40.36%
2014-12-31 $4.72B $13.74B 37.96%
2014-09-30 $4.74B $12.69B 39.02%
2014-06-30 $4.72B $11.71B 39.35%
2014-03-31 $4.61B $11.62B 38.83%
2013-12-31 $4.49B $12.53B 38.21%
2013-09-30 $4.38B $12.10B 38.30%
2013-06-30 $4.20B $11.26B 37.42%
2013-03-31 $3.94B $11.06B 35.71%
2012-12-31 $3.70B $11.35B 33.77%
2012-09-30 $3.53B $11.20B 31.65%
2012-06-30 $3.36B $10.54B 29.76%
2012-03-31 $3.24B $10.79B 27.82%
2011-12-31 $3.16B $12.09B 27.16%
2011-09-30 $3.06B $11.78B 26.94%
2011-06-30 $2.94B $11.88B 27.03%
2011-03-31 $2.77B $10.82B 26.76%
2010-12-31 $2.62B $10.95B 25.77%
2010-09-30 $2.35B $9.89B 23.53%
2010-06-30 $2.23B $9.76B 22.20%
2010-03-31 $2.15B $10.07B 21.61%
2009-12-31 $2.03B $10.25B 21.13%
2009-09-30 $1.99B $10.10B 20.78%
2009-06-30 $1.98B $9.37B 20.80%
2009-03-31 $1.76B $8.79B 18.15%
2008-12-31 $1.72B $9.97B 17.37%
2008-09-30 $1.50B $9.90B 15.60%
2008-06-30 $1.36B $10.18B 14.56%
2008-03-31 $1.69B $9.55B 18.79%
2007-12-31 $1.56B $8.78B 18.10%
2007-09-30 $1.66B $8.96B 20.09%
2007-06-30 $1.56B $8.74B 19.74%
2007-03-31 $1.19B $7.88B 15.81%
2006-12-31 $1.09B $7.51B 15.03%
2006-09-30 $1.00B $7.48B 14.08%
2006-06-30 $1.00B $7.25B 14.56%
2006-03-31 $0.99B $6.65B 15.12%
2005-12-31 $1.02B $7.01B 15.65%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $108.639B $16.962B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $387.009B 18.15
Pfizer (PFE) United States $255.437B 14.40
Novartis AG (NVS) Switzerland $202.383B 17.29
Merck (MRK) United States $199.761B 17.31
AbbVie (ABBV) United States $132.837B 11.79
Eli Lilly (LLY) United States $116.324B 20.45
Sanofi (SNY) France $113.065B 14.00
AstraZeneca (AZN) United Kingdom $104.862B 13.02
GlaxoSmithKline (GSK) United Kingdom $101.405B 13.63
Bristol-Myers Squibb (BMY) United States $85.837B 14.14